Valorum Oncology

Valorum Oncology is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company's lead asset, VAL-201, is a first-in-class peptide designed to inhibit the specific signaling pathway between the androgen receptor and SRC kinase. This mechanism aims to suppress tumor growth in hormone-dependent cancers, such as prostate cancer, without the side effects typically associated with complete hormone ablation. Valorum was founded by a team of seasoned industry executives with significant experience in oncology drug development and commercialization. The company operates under a lean business model, utilizing strategic partnerships to advance its clinical programs through mid-stage development.